Sort
15,273 grants matching “antimicrobial resistance”
Alpha-AApeptides as a novel class of antimicrobial biomaterials
$298,078Jianfeng Cai · University Of South Florida · R01 · FY2015 · GM
Impacts of Green Infrastructure on the Microbiome of Urban Stormwater: Reducing Threats to Public Health
$298,077Jay Martin · Ohio State University, The · · FY2018 · ENG
High throughput antibiotic discovery from the uncultivated microbial majority.
$298,076Amy Lynn Spoering · Novobiotic Pharmaceuticals, Llc · R43 · FY2010 · AI
Biology of Infectious Diseases Training Program
$298,058Matthew G Dorsey · University Of California, San Francisco · T32 · FY2018 · AI
High Throughput Screening to Discover Bacterial DNA Gyrase Poisoning Inhibitors
$298,045Fenfei Leng · Top Biosciences, Llc · R41 · FY2024 · TR
THE OUTER MEMBRANE AS A VIRULENCE PLATFORM
$297,950David Alan Hunstad · Washington University · R01 · FY2012 · DK
THE OUTER MEMBRANE AS A VIRULENCE PLATFORM
$297,950David Alan Hunstad · Washington University · R01 · FY2011 · DK
THE T-CELL RESPONSE TO ANTIGEN
$297,931Dana-Farber Cancer Institute · R01 · FY2004 · AI
MECHANISMS OF VIRULENCE GENE REGULATION IN S. AUREUS
$297,848U.S. Agriculture Research Service-Midsou · R01 · FY2003 · AI
Molecular analysis of accurate ribosomal translocation
$297,777Kurt L Fredrick · Ohio State University · R01 · FY2022 · GM
New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission
$297,748Anthony D Harris · University Of Maryland Baltimore · R01 · FY2008 · CI
Therapeutic Agents Targeting Cryptococcal Infections
$297,725Dennis L Wright · Quercus Molecular Design, Llc · R41 · FY2024 · AI
Selective agents against C. difficile infection
$297,718Dallas Hughes · Novobiotic Pharmaceuticals, Llc · R43 · FY2015 · AI
Ocular Disposition of Antimicrobial Agents
$297,615Ashim K Mitra · University Of Missouri Kansas City · R01 · FY2010 · EY
Lipid Effector Molecules of Innate Immunity: Antimicrobial Cholesteryl Esters
$297,495Edith Porter · California State University Los Angeles · SC1 · FY2011 · GM
Narrow-spectrum Agents Acting against Helicobacter pylori
$297,456Kenneth Coleman · Arietis · R44 · FY2012 · AI
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia
$297,455Carl Neil Kraus · Arrevus, Inc. · R42 · FY2018 · AI
Synthetic and biological investigations of 2-aminoimidazole derived natural products.
$297,375Ryan Edward Looper · University Of Utah · R01 · FY2019 · GM
Envelope biogenesis in Gram-negative bacteria
$297,337Natividad Ruiz · Ohio State University · R35 · FY2024 · GM
MOLECULAR EVOLUTION OF ENTERIC BACTERIOCINS
$297,249Yale University · R01 · FY2002 · GM
Bioorganic mechanism of peptide antibiotics
$297,196Dewey G McCafferty · Duke University · R01 · FY2009 · AI
Bioorganic mechanism of peptide antibiotics
$297,196Dewey G McCafferty · Duke University · R01 · FY2008 · AI
EF-Tu binding Tetrazoles targeting MDR Neisseria gonorrhoeae
$297,193Zachary David Aron · Microbiotix, Inc · R43 · FY2018 · AI
TRANSMIT: Training Research Acumen iN Students Modeling Infectious Threats
$297,120Lindsay T. Keegan · University Of Utah · U01 · FY2022 · CK
Device for rapid extraction of rare pathogens from raw samples
$297,090Jay Kenneth Fisher · Redbud Labs, Inc. · R43 · FY2016 · AI